Raymond Cohen: Well, I think they’re mutually exclusive, quite frankly. We’re — once again, we’re not looking at DTC as a driver of our business. We kind of look at it like that’s the icing on top, right? And we’re playing the long game. The DTC is about playing the long game for us, really counterprogramming messages that people are hearing on television that are ads that are suggesting it’s normal to leak urine. And if you just take my pill or where my panties or whatever or adult diapers or whatever it is, then everything is great. So we’re the company that’s doing the counter programming. But I want to emphasize that DTC is not the driver of our business. It’s all the other initiatives that we’ve talked about and some of which I mentioned in the script today, that are really driving the business.
Now having said that, our customers really appreciate the fact that we’re on the airways and that we’re providing these messages to folks and some of the — some of this is going to be difficult to measure, right? There’s additional benefit where not everybody is going to fill out a symptom questionnaire. Not everybody is going to go to the website. Some of them just walk right into these offices and say, asking about Axonics — asking about Axonics therapy. Now of course, when they walk into a customer location that doesn’t offer Axonics and they go tell me about Axonics therapy, they go, “Yes, we got that, too. It’s called InterStim right?” I’m still waiting for the thank you card from our competitor for doing national television but that hasn’t been forthcoming.
So in any event, hopefully, that gives you a reasonably colorful answer to your question.
Operator: I show no further questions at this time. I would now like to turn the call back to Raymond Cohen for closing your remarks.
Raymond Cohen: Thank you, operator. I appreciate your help today. So in closing, I’d like to say that our mission-driven team remains committed to innovating, supporting our dedicated physician customers and their patients, raising awareness of our best-in-class therapies and we’re confident that Axonics will continue to grow rapidly and profitably in the years ahead as we continue to expand and penetrate the underserved and undertreated incontinence markets in which we participate. We remain grateful for the trust physicians, patients and shareholders have placed in Axonics. And as always, I would like to thank my colleagues in Irvine and our team in the field for our diligent efforts — for their diligent efforts and dedication to fulfilling the Axonics’ mission of improving the lives of adults with incontinence.
So, thank you so much for the call today. Appreciate all the questions from the analyst community and we look forward to seeing and speaking with you in the weeks and months ahead.
Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect. Everyone, have a great afternoon.
